Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Minerva Neurosciences Inc
NERVCurrent price
1.54 USD
-0.08 USD (-4.94%)
Last closed
1.62 USD
Company
www.minervaneurosciences.com
ISIN
US6033801068
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
15 315 568 USD
Yield for 12 month
-44.80 %
1Y
3Y
5Y
10Y
15Y
NERV
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. Address: 1500 District Avenue, Burlington, MA, United States, 01803
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
5.00 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-30 982 USD
Last Year
-8 513 USD
Current Quarter
-5 618 USD
Last Quarter
-7 746 USD
Key Figures NERV
1 year
3 years
5 years
10 years
EBITDA
-24 492 732 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-28.91 %
PEG Ratio
–
Return On Equity TTM
-675.09 %
Wall Street Target Price
5.00 USD
Revenue TTM
–
Book Value
-3.10 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
-16 838 947 USD
Earnings per share
-0.45 USD
Diluted Eps TTM
-0.45 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics NERV
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History NERV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:8
Payout Ratio
–
Last Split Date
21.06.2022
Stock Valuation NERV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
11.21
Enterprise Value Revenue
0.035
Price Sales TTM
1.87
Enterprise Value EBITDA
2.60
Price Book MRQ
2.68
Financials NERV
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators NERV
For 52 weeks
2.06 USD
13.49 USD
50 Day MA
2.38 USD
Shares Short Prior Month
23 378
200 Day MA
2.68 USD
Short Ratio
0.41
Shares Short
9 544
Short Percent
0.23 %
BeatStart